When will the patents on TENUATE DOSPAN expire, and when will TENUATE DOSPAN go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	TENUATE DOSPAN	diethylpropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	012546-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Tenute Dospan (diethylpropion hydrochloride extended-release tablets) is an amphetamine derivative prescribed for short-term adjunctive therapy in the management of exogenous obesity. Its investment profile is characterized by a niche market, mature product lifecycle, and the competitive landscape of weight-loss medications.

What is the current market positioning of Tenuate Dospan?

Tenuate Dospan targets the adult population requiring short-term obesity management. The drug is indicated for use in conjunction with diet and exercise. It is not a first-line treatment for obesity but rather an option for individuals who have not responded to other therapeutic approaches.

The global obesity market is substantial and growing, driven by increasing prevalence rates worldwide. However, the market for prescription appetite suppressants is segmented. Tenuate Dospan competes within the subset of drugs approved for short-term use. Its established history and known efficacy profile contribute to its market presence. The drug's extended-release formulation is designed to provide a consistent therapeutic effect over a 12-hour period, addressing patient adherence and convenience.

Key market considerations include:

Therapeutic Class: Amphetamine derivative, appetite suppressant.
Indication: Short-term adjunctive therapy for exogenous obesity.
Dosage Form: Extended-release tablet.
Target Population: Adults with obesity who require short-term management.
Market Share: Specific market share data for Tenuate Dospan within the broader obesity drug market is not publicly detailed. However, its position is within the segment of older, established appetite suppressants.

What is the patent and intellectual property landscape for Tenuate Dospan?

The original patents protecting Tenuate Dospan have expired. The primary patent for diethylpropion hydrochloride was filed in the late 1950s. The extended-release formulation likely had subsequent patent protection, but these are also generally expired for widely marketed generic versions.

Original Composition of Matter Patents: Expired.
Formulation Patents (Extended-Release): Likely expired.
Exclusivity Periods: Post-patent, market exclusivity is determined by regulatory bodies (e.g., FDA in the U.S.) and is typically 5 years for new chemical entities, 3 years for new clinical investigations, and 7 years for orphan drugs. Tenuate Dospan, as an older drug, would not qualify for these newer exclusivity periods based on its original approval.

The absence of current patent protection means the market for Tenuate Dospan is open to generic competition. Manufacturers producing generic versions of diethylpropion hydrochloride extended-release tablets can enter the market upon the expiration of relevant formulation or manufacturing patents. This competition significantly impacts pricing and revenue potential.

Who are the key manufacturers and competitors for Tenuate Dospan?

As a genericized drug, Tenuate Dospan is manufactured by multiple pharmaceutical companies. The original brand name manufacturer was Sanofi-Aventis (now Sanofi). However, various generic manufacturers now produce and market diethylpropion hydrochloride extended-release tablets.

Key Manufacturers (Generic Market):

Various generic pharmaceutical companies operating under different brand names and generic labels. Specific market participants can fluctuate.

Competitors in the Obesity Market:

The competitive landscape for obesity treatments is evolving rapidly, with newer pharmacotherapies entering the market. Tenuate Dospan competes indirectly with drugs approved for long-term obesity management.

Other Appetite Suppressants (Older/Short-Term Use):
- Phentermine (various formulations, often short-term)
- Benzphetamine
- Phendimetrazine
Newer Pharmacotherapies (Often Approved for Long-Term Use):
- GLP-1 Receptor Agonists:
  - Semaglutide (Wegovy, Ozempic) - Novo Nordisk
  - Liraglutide (Saxenda) - Novo Nordisk
  - Tirzepatide (Zepbound, Mounjaro) - Eli Lilly
- Other Mechanisms:
  - Naltrexone/Bupropion (Contrave) - Currax Pharmaceuticals
  - Orlistat (Xenical, Alli) - Various manufacturers

The emergence of highly effective, long-acting medications like GLP-1 receptor agonists has significantly altered the obesity treatment paradigm. These newer drugs offer greater efficacy for sustained weight loss and are often favored for chronic obesity management, potentially limiting the market for short-term appetite suppressants like Tenuate Dospan.

What are the financial and sales fundamentals of Tenuate Dospan?

As a genericized product, detailed sales data for Tenuate Dospan under its original brand name is no longer publicly reported by the brand manufacturer. Sales are now distributed among multiple generic manufacturers.

Key Financial Considerations for Generic Products:

Price Erosion: Generic competition leads to significant price reductions compared to the branded product.
Volume-Based Revenue: Revenue is primarily driven by sales volume rather than high per-unit pricing.
Market Access: Reimbursement from insurance providers and formulary placement are critical for sales volume.
Manufacturing Costs: Efficient manufacturing processes are essential for profitability.

Estimates and Market Trends:

While specific figures for Tenuate Dospan are unavailable, the broader market for older, short-term appetite suppressants has likely seen a decline in revenue share due to the introduction of more effective long-term obesity treatments.

Market Size of Appetite Suppressants: The market for prescription appetite suppressants is a subset of the larger obesity market. Reports from market research firms indicate the global obesity drug market is valued in the billions of dollars and is projected to grow substantially. However, the contribution of older, short-term agents like Tenuate Dospan is a smaller, less rapidly growing segment.
Revenue Drivers: For generic manufacturers, revenue depends on securing contracts with large pharmacy benefit managers (PBMs) and wholesalers, as well as maintaining consistent production and quality.
Profit Margins: Margins on generics are typically lower than on branded drugs, necessitating high sales volumes to achieve significant profitability.

What are the regulatory and clinical considerations for Tenuate Dospan?

Tenuate Dospan is regulated by health authorities such as the U.S. Food and Drug Administration (FDA). Its prescribing information includes specific warnings and contraindications.

Clinical Profile:

Mechanism of Action: Central nervous system stimulant, believed to affect appetite control centers in the brain.
Efficacy: Short-term weight loss, typically up to 12 weeks.
Side Effects: Common side effects include dry mouth, nervousness, insomnia, and constipation. More serious side effects can occur, including cardiovascular issues.
Contraindications: Contraindicated in patients with a history of cardiovascular disease, hyperthyroidism, glaucoma, agitated states, and those taking MAO inhibitors.
Controlled Substance Status: Diethylpropion is a Schedule IV controlled substance in the U.S., indicating a low potential for abuse relative to other controlled substances.

Regulatory Considerations:

Post-Marketing Surveillance: Like all medications, Tenuate Dospan is subject to post-marketing surveillance to monitor for adverse events.
Labeling Updates: Regulatory agencies can require updates to prescribing information based on new clinical data or safety concerns.
Generic Drug Approval: Generic versions must demonstrate bioequivalence to the reference listed drug.

Therapeutic Limitations:

The short-term indication limits its utility for chronic weight management. The emergence of drugs with proven long-term efficacy and safety profiles for obesity management poses a significant challenge to the market position of short-term agents. The FDA has also issued warnings regarding the cardiac safety of certain weight-loss drugs, which can influence prescribing patterns across the class.

What are the investment risks and opportunities associated with Tenuate Dospan?

Investing in Tenuate Dospan, or companies that manufacture it, presents specific risks and limited opportunities due to its generic status and market segment.

Investment Risks:

Intense Generic Competition: The primary risk is the highly competitive generic market, leading to continuous price erosion and pressure on profit margins.
Declining Market Share: The rise of more effective, long-term obesity treatments (e.g., GLP-1 agonists) significantly diminishes the demand for short-term appetite suppressants.
Regulatory Scrutiny: As a controlled substance with potential cardiovascular risks, Tenuate Dospan remains subject to regulatory oversight and potential labeling changes or restrictions.
Limited Growth Potential: The market for short-term obesity drugs is largely stagnant or declining, offering little opportunity for significant revenue growth.
Manufacturing Costs and Supply Chain: Maintaining cost-effective manufacturing and a reliable supply chain is crucial but challenging in the low-margin generic market.

Investment Opportunities:

Stable Demand for Niche Indication: While not a growth area, there will likely remain a consistent, albeit small, demand for short-term appetite suppressants for specific patient populations or as part of a broader, short-term weight management strategy.
Cost-Effective Manufacturing: Companies with highly efficient and low-cost manufacturing capabilities for diethylpropion hydrochloride extended-release tablets can potentially achieve profitability through volume sales.
Portfolio Diversification (for Generic Manufacturers): For a generic manufacturer, Tenuate Dospan might represent one product in a larger portfolio, contributing to overall revenue and market presence rather than being a standalone growth driver.

Given these factors, investment in Tenuate Dospan is generally suited for generic manufacturers focused on volume, cost efficiency, and stable, mature product lines, rather than for growth-oriented pharmaceutical investors. The primary value lies in its established, albeit small, market niche and the potential for cost-efficient production.

Key Takeaways

Tenuate Dospan is a genericized, short-term appetite suppressant with an expired patent landscape. Its market position is constrained by intense generic competition and the disruptive emergence of highly effective, long-acting obesity medications like GLP-1 receptor agonists. Investment opportunities are primarily within cost-efficient generic manufacturing aiming for volume sales rather than growth or market expansion. Regulatory oversight and potential safety concerns associated with its class also represent ongoing risks.

Frequently Asked Questions

What is the current patent status of Tenuate Dospan? All primary composition of matter and formulation patents for Tenuate Dospan have expired, allowing for widespread generic manufacturing.
What are the main competitors to Tenuate Dospan in the obesity market? Competitors include other older appetite suppressants like phentermine and newer pharmacotherapies such as semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda).
What is the primary risk for companies manufacturing Tenuate Dospan? The primary risk is severe price erosion due to extensive generic competition and the declining market relevance of short-term appetite suppressants.
Is Tenuate Dospan a controlled substance? Yes, diethylpropion is classified as a Schedule IV controlled substance in the United States.
What is the most significant factor influencing the future market for Tenuate Dospan? The development and widespread adoption of highly effective, long-term obesity treatments like GLP-1 receptor agonists is the most significant factor impacting the future market for Tenuate Dospan.

Citations

[1] U.S. Food & Drug Administration. (n.d.). FDA Drug Database. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] Sanofi. (n.d.). Sanofi Annual Reports. (Note: Specific historical reports may be archived and require specific retrieval). [3] Centers for Disease Control and Prevention. (n.d.). Overweight & Obesity Data and Statistics. Retrieved from https://www.cdc.gov/obesity/data/index.html [4] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act Schedules. Retrieved from https://www.dea.gov/drug-scheduling

TENUATE DOSPAN Drug Patent Profile

Which patents cover Tenuate Dospan, and when can generic versions of Tenuate Dospan launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenuate Dospan

AI Deep Research

Questions you can ask:

Summary for TENUATE DOSPAN

US Patents and Regulatory Information for TENUATE DOSPAN

Tenuate Dospan Investment Fundamentals